presentation

Phase II study on bortezomib (BTZ) in multiple relapsed or refractory pediatric acute lymphoblastic leukemia (rALL) : high response rate with a modestly intensive regimen including BTZ, not related to pharmacokinetics

Gertjan JL Kaspers, Denise Niewerth, Bram Wilhelm, Satianand Ramnarain, Hans Berkhof and 16 more Published in 2015

Reference details